The delta opioid receptor

A. M. Symons-Liguori, Todd W Vanderah

Research output: Chapter in Book/Report/Conference proceedingConference contribution

Abstract

The delta opioid receptor has become increasingly relevant to the development of analgesics since its discovery only a few decades past. The endogenous antinociceptive properties of the δOR in conjunction with the potential for δOR ligands to circumvent classical μ-opioid side effects and tolerance make the δOR a provocative alternative to current μOR-specific strategies. This chapter explores the clinical potential of δOR-mediated analgesia and discusses novel biochemical strategies for targeting the δOR. Finally, we evaluate the use of δOR ligands as co-therapies with new and classical analgesics. A greater understanding of δOR function and pharmacology will ultimately contribute to the development of innovative new strategies for the pharmacological management of pain.

Original languageEnglish (US)
Title of host publicationACS Symposium Series
PublisherAmerican Chemical Society
Pages223-244
Number of pages22
Volume1131
ISBN (Print)9780841227828
DOIs
StatePublished - 2013

Publication series

NameACS Symposium Series
Volume1131
ISSN (Print)00976156
ISSN (Electronic)19475918

Fingerprint

delta Opioid Receptor
Analgesics
Ligands
Opioid Analgesics

ASJC Scopus subject areas

  • Chemistry(all)
  • Chemical Engineering(all)

Cite this

Symons-Liguori, A. M., & Vanderah, T. W. (2013). The delta opioid receptor. In ACS Symposium Series (Vol. 1131, pp. 223-244). (ACS Symposium Series; Vol. 1131). American Chemical Society. https://doi.org/10.1021/bk-2013-1131.ch012

The delta opioid receptor. / Symons-Liguori, A. M.; Vanderah, Todd W.

ACS Symposium Series. Vol. 1131 American Chemical Society, 2013. p. 223-244 (ACS Symposium Series; Vol. 1131).

Research output: Chapter in Book/Report/Conference proceedingConference contribution

Symons-Liguori, AM & Vanderah, TW 2013, The delta opioid receptor. in ACS Symposium Series. vol. 1131, ACS Symposium Series, vol. 1131, American Chemical Society, pp. 223-244. https://doi.org/10.1021/bk-2013-1131.ch012
Symons-Liguori AM, Vanderah TW. The delta opioid receptor. In ACS Symposium Series. Vol. 1131. American Chemical Society. 2013. p. 223-244. (ACS Symposium Series). https://doi.org/10.1021/bk-2013-1131.ch012
Symons-Liguori, A. M. ; Vanderah, Todd W. / The delta opioid receptor. ACS Symposium Series. Vol. 1131 American Chemical Society, 2013. pp. 223-244 (ACS Symposium Series).
@inproceedings{5ad625b1182945f6adf2d4eda76148cf,
title = "The delta opioid receptor",
abstract = "The delta opioid receptor has become increasingly relevant to the development of analgesics since its discovery only a few decades past. The endogenous antinociceptive properties of the δOR in conjunction with the potential for δOR ligands to circumvent classical μ-opioid side effects and tolerance make the δOR a provocative alternative to current μOR-specific strategies. This chapter explores the clinical potential of δOR-mediated analgesia and discusses novel biochemical strategies for targeting the δOR. Finally, we evaluate the use of δOR ligands as co-therapies with new and classical analgesics. A greater understanding of δOR function and pharmacology will ultimately contribute to the development of innovative new strategies for the pharmacological management of pain.",
author = "Symons-Liguori, {A. M.} and Vanderah, {Todd W}",
year = "2013",
doi = "10.1021/bk-2013-1131.ch012",
language = "English (US)",
isbn = "9780841227828",
volume = "1131",
series = "ACS Symposium Series",
publisher = "American Chemical Society",
pages = "223--244",
booktitle = "ACS Symposium Series",

}

TY - GEN

T1 - The delta opioid receptor

AU - Symons-Liguori, A. M.

AU - Vanderah, Todd W

PY - 2013

Y1 - 2013

N2 - The delta opioid receptor has become increasingly relevant to the development of analgesics since its discovery only a few decades past. The endogenous antinociceptive properties of the δOR in conjunction with the potential for δOR ligands to circumvent classical μ-opioid side effects and tolerance make the δOR a provocative alternative to current μOR-specific strategies. This chapter explores the clinical potential of δOR-mediated analgesia and discusses novel biochemical strategies for targeting the δOR. Finally, we evaluate the use of δOR ligands as co-therapies with new and classical analgesics. A greater understanding of δOR function and pharmacology will ultimately contribute to the development of innovative new strategies for the pharmacological management of pain.

AB - The delta opioid receptor has become increasingly relevant to the development of analgesics since its discovery only a few decades past. The endogenous antinociceptive properties of the δOR in conjunction with the potential for δOR ligands to circumvent classical μ-opioid side effects and tolerance make the δOR a provocative alternative to current μOR-specific strategies. This chapter explores the clinical potential of δOR-mediated analgesia and discusses novel biochemical strategies for targeting the δOR. Finally, we evaluate the use of δOR ligands as co-therapies with new and classical analgesics. A greater understanding of δOR function and pharmacology will ultimately contribute to the development of innovative new strategies for the pharmacological management of pain.

UR - http://www.scopus.com/inward/record.url?scp=84905454968&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84905454968&partnerID=8YFLogxK

U2 - 10.1021/bk-2013-1131.ch012

DO - 10.1021/bk-2013-1131.ch012

M3 - Conference contribution

SN - 9780841227828

VL - 1131

T3 - ACS Symposium Series

SP - 223

EP - 244

BT - ACS Symposium Series

PB - American Chemical Society

ER -